Roche Holding AG Stock News

Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

The decline in sales of COVID-19 products hurt the company's 2022 bottom line. Many new treatments for cancers and other diseases are coming to market.

Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.

If approved, the test could streamline the diagnostic journey and help patients get earlier access to future Alzheimer's treatments, Roche said.

The company saw improved earnings in 2022 but predicts a small drop this year. Roche's stock is down 28% over the past year.

Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).

A U.S. Food and Drug Administration committee voted in favor of Roche Holding AG's Polivy antibody drug targeting untreated diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

David Roche, president of Independent Strategy, discusses the changing dynamics for the Chinese and global economy.

Two Barron's Annual Roundtable, plus one Bloomberg Intelligence article published late January listed 99 stocks of-note for 2023; 78 of those were unduplicated US publicly-listed companies, of which 5

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

U.S.-listed shares of Bayer AG BAYRY, +5.72% BAYER, +1.09% rallied about 5% in trading on Wednesday after the German pharmaceutical company said it named Bill Anderson as its new CEO, effective June 1

Bayer stock surged to an eight-month high Wednesday after the company named former Roche exec Bill Anderson as its new chief executive. The post Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Sha